Kartikeya Pharma
Kartikeya Pharma, a prominent player in the pharmaceutical industry, is headquartered in Indonesia (ID) and operates extensively across Southeast Asia. Founded in 2010, the company has established itself as a leader in the development and distribution of high-quality herbal supplements and nutraceuticals, with a particular focus on Ashwagandha products. Kartikeya Pharma's core offerings include KSM-66 Ashwagandha, renowned for its purity and efficacy, setting a benchmark in the market. The company prides itself on its commitment to quality, utilising advanced extraction techniques that preserve the full spectrum of the herb's benefits. With a strong market position, Kartikeya Pharma has garnered recognition for its innovative approach and dedication to promoting holistic health solutions.
DitchCarbon Score
How does Kartikeya Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Wood Products Other Than Furniture industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Kartikeya Pharma's score of 7 is higher than 92% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Kartikeya Pharma's reported carbon emissions
In 2023, Kartikeya Pharma reported total carbon emissions of approximately 56,053,320 kg CO2e for Scope 1, 223,014,700 kg CO2e for Scope 2, and 25,670,000 kg CO2e for Scope 3. This indicates a significant carbon footprint, particularly in Scope 2 emissions, which are primarily associated with energy consumption. Comparatively, in 2024, the emissions increased slightly, with Scope 1 emissions at about 67,705,110 kg CO2e, Scope 2 at 239,708,530 kg CO2e, and Scope 3 at 24,393,000 kg CO2e. This upward trend in emissions highlights the ongoing challenges the company faces in managing its carbon output. Currently, Kartikeya Pharma has not disclosed any specific reduction targets or initiatives aimed at decreasing its carbon emissions. The absence of a climate pledge or science-based targets suggests that the company may need to enhance its commitment to sustainability and climate action in the pharmaceutical industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2023 | 2024 | |
|---|---|---|
| Scope 1 | 56,053,320 | 00,000,000 |
| Scope 2 | 223,014,700 | 000,000,000 |
| Scope 3 | 25,670,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Kartikeya Pharma is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
